Methods and compositions for treating mesothelioma and small lung cancer that express midkine
US-10668078-B2 · Jun 2, 2020 · US
Methods and compositions for treating mesothelioma and small lung cancer that express midkine
US11026950B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11026950-B2 |
| Application number | US-202016857285-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 24, 2020 |
| Priority date | Jul 28, 2016 |
| Publication date | Jun 8, 2021 |
| Grant date | Jun 8, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Embodiments provided herein relate to methods and compositions for treating mesothelioma and/or a small cell lung cancer that express midkine.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating malignant mesothelioma, comprising the step of administering to an individual in need thereof, an effective amount of a pharmaceutical composition comprising a compound selected from or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier. 2. The method of claim 1 , wherein said compound is: or a pharmaceutically acceptable salt thereof. 3. The method of claim 1 , wherein the compound is administered with 4. The method of claim 1 , further comprising the step of administering to said individual a therapeutically effective amount of a BCL-2 inhibitor. 5. The method of claim 1 , wherein said individual is mammalian. 6. The method of claim 1 , wherein said individual is human. 7. The method of claim 4 , wherein said BCL-2 inhibitor is selected from ABT-737, ABT-199, GDC-0199, GX15-070 (Obatoclax), and combinations thereof.
Assignees
Inventors
Classifications
containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone · CPC title
Antineoplastic agents · CPC title
- A61K31/5377Primary
not condensed and containing further heterocyclic rings, e.g. timolol · CPC title
containing further heterocyclic ring systems · CPC title
the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11026950B2 cover?
- Embodiments provided herein relate to methods and compositions for treating mesothelioma and/or a small cell lung cancer that express midkine.
- Who is the assignee on this patent?
- Childrens Hospital Med Ct
- What technology area does this patent fall under?
- Primary CPC classification A61K31/5377. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).